Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE3
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
- Status
- COMPLETED
- Phase
- PHASE2
Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects
- Status
- TERMINATED
- Phase
- PHASE3
Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients
- Status
- COMPLETED
- Phase
- PHASE1
Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients
- Status
- UNKNOWN
- Phase
- PHASE1
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
- Status
- COMPLETED
- Phase
- PHASE3
Lenvatinib and Pembrolizumab Simultaneous Combination Study
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1
Pembrolizumab in Treating Participants With Leukoplakia
- Status
- RECRUITING
- Phase
- PHASE2
Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2